ERBB2 and breast cancer: The oral FASN inhibitor TVB-2640 combined with different cancer treatments has been assessed in clinical trials, including combined paclitaxel and trastuzumab for human growth factor receptor-2 (HER2)-positive advanced breast cancer (52), combined paclitaxel for patients with heavily pretreated breast cancer, and combined bevacizumab for high-grade astrocytoma (53).